Rocket Pharmaceuticals (RCKT) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Rocket Pharmaceuticals is the larger company by market cap ($281.0 million vs $260.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RCKT | VOGX |
|---|---|---|
| Share price | $2.56 | $17.56 |
| Market cap | $281.02M | $260.86M |
| 1-day change | -2.66% | +0.40% |
| YTD return | -27.07% | — |
| 1-year return | -30.25% | — |
| 5-year return | -90.83% | — |
| EPS (TTM) | $-0.17 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $38.41 |
| 52-week low | $2.42 | $12.95 |
| Distance from 52-week high | -53.03% | -54.28% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +232.03% | +213.21% |
| Average volume | 1.67M | 187.66K |
| Shares outstanding | 109.77M | 14.86M |
| Employees | 202 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
RCKT vs VOGX FAQ
Which is bigger, Rocket Pharmaceuticals or Vogenx?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $281.02M compared with $260.86M for Vogenx (VOGX).
Are Rocket Pharmaceuticals and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.